Q3 2022 13F Holders as of 30 Sep 2022
-
Type / Class
-
Equity / Common Stock, par value $0.001 par value per share
-
Shares outstanding
-
73,819,979
-
Total 13F shares
-
25,783,847
-
Share change
-
+1,104,604
-
Total reported value
-
$954,470,507
-
Put/Call ratio
-
205%
-
Price per share
-
$37.02
-
Number of holders
-
131
-
Value change
-
+$46,796,895
-
Number of buys
-
76
-
Number of sells
-
45
Institutional Holders of RELMADA THERAPEUTICS, INC. - Common Stock, par value $0.001 par value per share (RLMD) as of Q3 2022
As of 30 Sep 2022,
RELMADA THERAPEUTICS, INC. - Common Stock, par value $0.001 par value per share (RLMD) was held by
131 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
25,783,847 shares.
The largest 10 holders included
RTW INVESTMENTS, LP, PERCEPTIVE ADVISORS LLC, BlackRock Inc., BVF INC/IL, RA CAPITAL MANAGEMENT, L.P., VR Adviser, LLC, VANGUARD GROUP INC, CITADEL ADVISORS LLC, Point72 Asset Management, L.P., and Vivo Capital, LLC.
This page lists
131
institutional shareholders reporting positions in this security
for the Q3 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.